» Articles » PMID: 22892876

Galectin-3 Expression in Prostate Cancer and Benign Prostate Tissues: Correlation with Biochemical Recurrence

Overview
Journal World J Urol
Specialty Urology
Date 2012 Aug 16
PMID 22892876
Citations 26
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Galactin-3 is a cell adhesion molecule involved in tumor progression. Our aim was to examine Gal-3 expression in tumor, benign tissue adjacent to the tumor (adjacent-benign) and benign prostate specimens and correlated it with biochemical recurrence.

Materials And Methods: Tissue microarrays were prepared from 83 tumor, 78 adjacent-benign and 75 benign tissues obtained from 83 patients undergoing prostatectomy for clinically localized prostate cancer. Tissues were stained using a Gal-3 antibody and immunohistochemistry. The staining was graded between 0 and 300 depending upon staining intensity and the area of staining. In 37 patients on whom there was follow-up (Mean: 57.8 months; Median: 68 months), staining intensity was correlated with biochemical recurrence.

Results: Gal-3 showed both nuclear and cytoplasmic localization in benign, adjacent-benign and tumor tissues. Median Gal-3 staining scores significantly decreased from benign (192.5) to adjacent-benign (148.8 p = 0.007) and to tumor (108.8; p < 0.0001) tissues. In univariate analysis, age (p = 0.028), Gleason sum (p = 0.007), T stage (p = 0.011), seminal vesicle invasion (p = 0.009), pre-operative prostate-specific antigen (p = 0.045) and Gal-3 staining in tumor tissues (0.018) significantly correlated with biochemical recurrence. In multivariate analysis, Gal-3 expression in tumor (p = 0.04), adjacent-benign (p = 0.037) and benign (p = 0.005) tissues significantly correlated with biochemical recurrence. Gal-3 staining in tumor tissues had 91.7 % sensitivity, 64 % specificity and 73 % accuracy in predicting biochemical recurrence.

Conclusions: This is the first study that showed a decreasing gradient of Gal-3 expression in benign, adjacent-benign and tumor tissues. Gal-3 expression may be useful in predicting biochemical recurrence.

Citing Articles

A Novel Signature Based on Anoikis Associated with BCR-Free Survival for Prostate Cancer.

Yang C, Yu T, Lin Q Biochem Genet. 2023; 61(6):2496-2513.

PMID: 37118620 DOI: 10.1007/s10528-023-10387-9.


Gal-3 Protein Expression and Localization in Prostate Tumours.

Lima T, Macedo-Silva C, Felizardo D, Fraga J, Carneiro I, Jeronimo C Curr Oncol. 2023; 30(3):2729-2742.

PMID: 36975419 PMC: 10047320. DOI: 10.3390/curroncol30030206.


Estrogen receptors regulate galectin‑3 in androgen‑independent DU‑145 prostate cancer cells.

Souza D, Macheroni C, Vicente C, Cavalheiro R, Campo V, Porto C Oncol Rep. 2023; 49(5).

PMID: 36960864 PMC: 10086566. DOI: 10.3892/or.2023.8530.


Molecular regulation of prostate cancer by Galectin-3 and estrogen receptor.

Souza D, Macheroni C, Pereira G, Vicente C, Porto C Front Endocrinol (Lausanne). 2023; 14:1124111.

PMID: 36936148 PMC: 10020622. DOI: 10.3389/fendo.2023.1124111.


Galectin functions in cancer-associated inflammation and thrombosis.

Kruk L, Braun A, Cosset E, Gudermann T, Mammadova-Bach E Front Cardiovasc Med. 2023; 10:1052959.

PMID: 36873388 PMC: 9981828. DOI: 10.3389/fcvm.2023.1052959.


References
1.
Merseburger A, Kramer M, Hennenlotter J, Simon P, Knapp J, Hartmann J . Involvement of decreased Galectin-3 expression in the pathogenesis and progression of prostate cancer. Prostate. 2007; 68(1):72-7. DOI: 10.1002/pros.20688. View

2.
Barondes S, Cooper D, Gitt M, Leffler H . Galectins. Structure and function of a large family of animal lectins. J Biol Chem. 1994; 269(33):20807-10. View

3.
Deutscher S, Figueroa S, Kumar S . Tumor targeting and SPECT imaging properties of an (111)In-labeled galectin-3 binding peptide in prostate carcinoma. Nucl Med Biol. 2009; 36(2):137-46. DOI: 10.1016/j.nucmedbio.2008.10.015. View

4.
van den Brule F, Waltregny D, Liu F, Castronovo V . Alteration of the cytoplasmic/nuclear expression pattern of galectin-3 correlates with prostate carcinoma progression. Int J Cancer. 2000; 89(4):361-7. DOI: 10.1002/1097-0215(20000720)89:4<361::aid-ijc8>3.0.co;2-u. View

5.
Bartolazzi A, Gasbarri A, Papotti M, Bussolati G, Lucante T, Khan A . Application of an immunodiagnostic method for improving preoperative diagnosis of nodular thyroid lesions. Lancet. 2001; 357(9269):1644-50. DOI: 10.1016/s0140-6736(00)04817-0. View